Wire by Fusion42
Fusion42 Scout Raise
The Debrief & Outliers
Regulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers
Benchmarks
Benchmarks HomeBy News TypeBy RegionBy Sector
AI WeeklyAbout

Switch product

Fusion42RaiseScoutWire

The Debrief & Outliers

All editionsRegulatory RadarWorkday Debrief · Mon 09:00 UTCSector Deep DiveWorkday Debrief · Tue 09:00 UTCGeo PulseWorkday Debrief · Wed 09:00 UTCOperating ConditionsWorkday Debrief · Thu 09:00 UTCWeekly BriefingWorkday Debrief · Fri 09:00 UTCWTF Happened This WeekSat 09:00 UTC · 3σ outliers

Database & benchmarks

Benchmarks HomeBy News TypeBy RegionBy SectorStories

Account

Sign in
← Back

Wire · opportunities

NIAID Awards Zepto Life Technology up to $8.9M to Develop Liquid Biopsy for Infectious Disease

11 August 2026 · By · Wire by Fusion42

Published

11 August 2026

Topic

opportunities

◆ Sectors

Diagnostics

◆ Geography

United States

◆ Source

Read at genomeweb.com →

◆ Verified

Fusion42 · 11 August 2026 · Fusion42 review

The US National Institute of Allergy and Infectious Diseases (NIAID) has awarded Zepto Life Technology up to $8.9 million to develop a liquid biopsy platform specifically targeting infectious diseases.

This Wire brief sits within Fusion42's coverage of Diagnostics, and 2 sources have reported it between 11 Aug 2026 and 13 Aug 2026.

◆ ◆ The Wire takeaway

You are entering early-stage infectious disease diagnostics with a fresh tool that can redefine testing speed and accuracy. Winning government funding highlights a clear route to accelerated development and market credibility right now.

◆ Coverage

2 sources · first reported 11 Aug 2026 · latest 13 Aug 2026

◆ Related on Wire

◆ Topics

Diagnosticsliquid-biopsyinfectious-diseasenih-fundingdiagnosticsbiotech